Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K5 | Q99683 | 3/20 | 0.59 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.55 |
| ▸ | MAP4K1 | Q92918 | 2/20 | 0.53 |
| ▸ | JUN | P05412 | 2/20 | 0.49 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.49 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.48 |
| ▸ | ROCK2 | O75116 | 6/20 | 0.47 |
| ▸ | AKT1 | P31749 | 1/20 | 0.46 |
| ▸ | AKT2 | P31751 | 1/20 | 0.46 |
| ▸ | PLK1 | P53350 | 1/20 | 0.46 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.45 |
| ▸ | ILK | Q13418 | 1/20 | 0.43 |
| ▸ | BRAF | P15056 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzene SCHEMBL28188863 | 0.77 | MAP3K5 (0.60) | MAP3K5ROCK1MAPK8 | |
| SCHEMBL31381352 | 0.77 | MAP3K5 (0.60) | MAP3K5ROCK1MAPK8 | |
| SCHEMBL167891 | 0.77 | MAP3K5 (0.60) | MAP3K5ROCK1MAPK8 | |
| SCHEMBL27770482 | 0.77 | MAP3K5 (0.60) | MAP3K5ROCK1MAPK8 | |
| SCHEMBL4573935 | 0.76 | MAP3K5 (0.58) | MAP3K5ROCK1MAPK8 | |
| Hydrochloric Acid SCHEMBL8807679 | 0.76 | MAP3K5 (0.58) | MAP3K5ROCK1MAPK8 | |
| Hydrochloric Acid SCHEMBL8810105 | 0.76 | ROCK1 (0.52) | MAP3K5ROCK1MAP4K1MAPK8BRAF | |
| SCHEMBL1632143 | 0.75 | MAP4K1 (0.58) | MAP3K5MAP4K1JUNMAPK10MAPK8 | |
| SCHEMBL30512124 | 0.75 | MAP4K1 (0.61) | MAP3K5MAP4K1JUNMAPK10MAPK8 | |
| SCHEMBL30512106 | 0.75 | MAP3K5 (0.61) | MAP3K5MAP4K1JUNMAPK10MAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260102406-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | NEUPHARMA INC (US) | 2026-04-16 | — | — | US | disclosed |
| US-12403145-B2 | Substituted quinazolines for inhibiting kinase activity | NEUPHARMA, INC (US) | 2025-09-02 | — | — | US | disclosed |
| US-20240197752-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | NEUPHARMA INC | 2024-06-20 | — | — | US | disclosed |
| US-11865120-B2 | Substituted quinazolines for inhibiting kinase activity | NEUPHARMA, INC. (US) | 2024-01-09 | — | — | US | disclosed |
| US-20220354864-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | NEUPHARMA, INC. | 2022-11-10 | — | — | US | disclosed |
| US-11304957-B2 | Substituted quinazolines for inhibiting kinase activity | NEUPHARMA, INC. (US) | 2022-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240197752-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | DCK, ABL1, MAP4K2 | MAP3K5 8/4885ROCK1 544/4885MAP4K1 16/4885 |
| US-11865120-B2 | Substituted quinazolines for inhibiting kinase activity | DCK, ABL1, MAP4K2 | MAP3K5 8/4885ROCK1 544/4885MAP4K1 16/4885 |
| US-12403145-B2 | Substituted quinazolines for inhibiting kinase activity | DCK, ABL1, MAP4K2 | MAP3K5 8/4885ROCK1 544/4885MAP4K1 16/4885 |
| US-11304957-B2 | Substituted quinazolines for inhibiting kinase activity | DCK, ABL1, MAP4K2 | MAP3K5 8/4885ROCK1 544/4885MAP4K1 16/4885 |
| US-20220354864-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | DCK, ABL1, MAP4K2 | MAP3K5 8/4885ROCK1 544/4885MAP4K1 16/4885 |
| US-20260102406-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | BRAF, TTK, MAP4K2 | MAP3K5 35/4885ROCK1 693/4885MAP4K1 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.